AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8002638 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT (uracil and tegafur) 400 mg/day for 1 year
Number of subjects: 112
Study 8002638 — intervention group
Group type: COMPARATOR
Intervention: No treatment (group A)
Number of subjects: 112
Study 2790692 — intervention group
Group type: EXPERIMENTAL
Intervention: CT + RT (Continuous 5-FU infusion followed by hepatic irradiation of 25.5 Gy)
Number of subjects: 37
Study 2790692 — intervention group
Group type: COMPARATOR
Intervention: CT (Continuous 5-FU infusion)
Number of subjects: 37
Study 2790692 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with 4+ vascularity
Number of subjects: 37
Study 2790692 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with Grade 1, well-differentiated histologic type
Number of subjects: 37
Study 2790692 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with both 4+ vascularity and Grade 1 histologic type
Number of subjects: 37
Study 801578 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (0.1 mg reinjection)
Number of subjects: 0
Study 801578 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfentanil (0.01 mg reinjection)
Number of subjects: 0
Study 801578 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (0.5 mg reinjection)
Number of subjects: 0
Study 801578 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfentanil (0.05 mg reinjection)
Number of subjects: 0
Study 801578 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (0.1 mg reinjection) with droperidol (1.25 mg)
Number of subjects: 0
Study 801578 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfentanil (0.01 mg reinjection) with droperidol (1.25 mg)
Number of subjects: 0
Study 31376790 — intervention group
Group type: EXPERIMENTAL
Intervention: History of living in OHC
Number of subjects: 202
Study 31376790 — intervention group
Group type: EXPERIMENTAL
Intervention: Living in OHC during childhood
Number of subjects: 202
Study 31376790 — intervention group
Group type: EXPERIMENTAL
Intervention: History of OHC and suicidal ideation
Number of subjects: 202
Study 31376790 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants living in group home, foster care, and/or psychiatric facility
Number of subjects: 202
Study 30677829 — intervention group
Group type: EXPERIMENTAL
Intervention: Notable Protagonists (NP)
Number of subjects: 476
Study 30677829 — intervention group
Group type: COMPARATOR
Intervention: Generic Protagonists (GP)
Number of subjects: 476
Study 26798983 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 0
Study 26798983 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin dose
Number of subjects: 0
Study 26798983 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycemic control
Number of subjects: 0
Study 26798983 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronologic age
Number of subjects: 0
Study 24508337 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety audits based on a checklist of 37 measures
Number of subjects: 50
Study 22305777 — intervention group
Group type: EXPERIMENTAL
Intervention: SureFil(®) SDR™ (Dentsply, S)
Number of subjects: 30
Study 22305777 — intervention group
Group type: COMPARATOR
Intervention: Calibra (Dentsply, C)
Number of subjects: 30
Study 22305777 — intervention group
Group type: EXPERIMENTAL
Intervention: Post type
Number of subjects: 30
Study 22305777 — intervention group
Group type: EXPERIMENTAL
Intervention: Post space level
Number of subjects: 30
Study 22305777 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-cement interaction
Number of subjects: 30
Study 22305777 — intervention group
Group type: EXPERIMENTAL
Intervention: Failure mode assessment
Number of subjects: 30
Study 19926626 — intervention group
Group type: EXPERIMENTAL
Intervention: Event drawing (n = 69)
Number of subjects: 125
Study 19926626 — intervention group
Group type: COMPARATOR
Intervention: No event drawing (n = 56)
Number of subjects: 125
Study 17903073 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined continuous ethinyl estradiol (10 microg) and norethindrone acetate (1 mg) given once daily for 3 months
Number of subjects: 18
Study 17903073 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined continuous ethinyl estradiol and norethindrone acetate
Number of subjects: 18
Study 17903073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 16131023 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt supplementation (125 g, 5 days a week for 9 months)
Number of subjects: 402
Study 16131023 — intervention group
Group type: COMPARATOR
Intervention: Control group (no yogurt supplementation)
Number of subjects: 402
Study 12634038 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwives' knowledge and attitudes regarding baby walkers
Number of subjects: 65
Study 12634038 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwives' knowledge of baby walker injury risk
Number of subjects: 65
Study 12634038 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitude scales regarding baby walkers
Number of subjects: 65
Study 12634038 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal experience with baby walkers
Number of subjects: 65
Study 10716205 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial expressions presented in the blind field to the blindsight subject (GY)
Number of subjects: 1
Study 7489435 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 0.5 mg/kg
Number of subjects: 35
Study 7489435 — intervention group
Group type: COMPARATOR
Intervention: Control (wound infiltration with bupivacaine 0.5%)
Number of subjects: 35
Study 1942990 — intervention group
Group type: EXPERIMENTAL
Intervention: bemitil (0.25‐0.5 g/day orally for 5‐7 days)
Number of subjects: 66
Study 1942990 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 66
Study 7452507 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/day p.o.)
Number of subjects: 12
Study 7452507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7452507 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 12
Study 7452507 — intervention group
Group type: EXPERIMENTAL
Intervention: Heroin self-administration
Number of subjects: 12
Study 6520821 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative cefoxitin irrigation
Number of subjects: 103
Study 6520821 — intervention group
Group type: COMPARATOR
Intervention: Short course of intravenous cefoxitin prophylaxis and intraoperative saline irrigation
Number of subjects: 103
Study 31187949 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetabular diameter (AD) measurement
Number of subjects: 200
Study 31187949 — intervention group
Group type: EXPERIMENTAL
Intervention: Transverse acetabular diameter (TAD) measurement
Number of subjects: 200
Study 31187949 — intervention group
Group type: EXPERIMENTAL
Intervention: Discriminant function using both acetabular variables
Number of subjects: 200
Study 31187949 — intervention group
Group type: COMPARATOR
Intervention: Inter-observer error measurement
Number of subjects: 200
Study 29212135 — intervention group
Group type: EXPERIMENTAL
Intervention: Panic-Focused Psychodynamic Psychotherapy (PFPP)
Number of subjects: 118
Study 29212135 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 118
Study 26721648 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 125
Study 26721648 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 125
Study 25253199 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial combination therapy (iCombo)
Number of subjects: 508
Study 25253199 — intervention group
Group type: COMPARATOR
Intervention: Initial monotherapy (iMono)
Number of subjects: 508
Study 23173697 — intervention group
Group type: EXPERIMENTAL
Intervention: Tradamixina (150 mg of Alga Ecklonia Bicyclis, 396 mg of Tribulus Terrestris and 144 mg of D‐Glucosamine and N‐Acetyl‐D‐Glucosamine) twice a day for 2 months
Number of subjects: 70
Study 23173697 — intervention group
Group type: COMPARATOR
Intervention: Tadalafil 5 mg daily for 2 months
Number of subjects: 70
Study 20438867 — intervention group
Group type: EXPERIMENTAL
Intervention: OAM (Omeprazole, Amoxicillin and Metronidazole)
Number of subjects: 0
Study 20438867 — intervention group
Group type: COMPARATOR
Intervention: Curcumin
Number of subjects: 0
Study 17353942 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine (0.3 mg/kg, given orally) plus a nutritionally balanced amino acid mixture
Number of subjects: 14
Study 17353942 — intervention group
Group type: COMPARATOR
Intervention: acute phenylalanine/tyrosine depletion (APTD)
Number of subjects: 14
Study 17353942 — intervention group
Group type: EXPERIMENTAL
Intervention: L-DOPA (Sinemet, 2 x 100 mg/25 mg)
Number of subjects: 14
Study 16223394 — intervention group
Group type: EXPERIMENTAL
Intervention: Inferior-medial injection technique
Number of subjects: 100
Study 16223394 — intervention group
Group type: COMPARATOR
Intervention: Inferior-superior injection technique
Number of subjects: 100
Study 12574218 — intervention group
Group type: EXPERIMENTAL
Intervention: High Protein (HP) diet; 40% carbohydrate and 30% protein
Number of subjects: 28
Study 12574218 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Protein (LP) diet; 55% carbohydrate and 15% protein
Number of subjects: 28
Study 10533826 — intervention group
Group type: EXPERIMENTAL
Intervention: RBCs stored for 6 weeks at 4 degrees C
Number of subjects: 11
Study 10533826 — intervention group
Group type: EXPERIMENTAL
Intervention: RBCs stored for 5 weeks at 4 degrees C except for 24 hours at 25 degrees C on Day 14
Number of subjects: 11
Study 10533826 — intervention group
Group type: EXPERIMENTAL
Intervention: RBCs stored for 5 weeks at 4 degrees C except for 24 hours at 25 degrees C on Day 28
Number of subjects: 11
Study 10533826 — intervention group
Group type: EXPERIMENTAL
Intervention: RBCs stored in AS-5 and allowed to warm to 25 degrees C for 24 hours
Number of subjects: 11
Study 8704534 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin T positive group
Number of subjects: 460
Study 8704534 — intervention group
Group type: COMPARATOR
Intervention: Troponin T negative group
Number of subjects: 460
Study 1922801 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release bromocriptine (14.2 +/- 0.7 mg/d, taken twice a day)
Number of subjects: 243
Study 1922801 — intervention group
Group type: COMPARATOR
Intervention: Standard bromocriptine (13.5 +/- 0.7 mg/d, taken three times a day)
Number of subjects: 243
Study 1922801 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release bromocriptine
Number of subjects: 243
Study 1922801 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release bromocriptine and Standard bromocriptine
Number of subjects: 243
Study 6297068 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacarbazine (DTIC) + Detorubicin (120 mg/m2, IV every three weeks)
Number of subjects: 51
Study 6297068 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine (DTIC) alone (250 mg/m2, IV, over 4 days every three weeks)
Number of subjects: 51
Study 6297068 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacarbazine (DTIC) + Detorubicin
Number of subjects: 51
Study 6297068 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine (DTIC) alone
Number of subjects: 51
Study 31964380 — intervention group
Group type: EXPERIMENTAL
Intervention: AL + day 1 primaquine (0.75 mg/kg)
Number of subjects: 111
Study 31964380 — intervention group
Group type: EXPERIMENTAL
Intervention: AL + day 3 primaquine (0.75 mg/kg)
Number of subjects: 111
Study 31964380 — intervention group
Group type: COMPARATOR
Intervention: AL only
Number of subjects: 111
Study 31964380 — intervention group
Group type: EXPERIMENTAL
Intervention: AL only and AL + day 1 primaquine
Number of subjects: 111
Study 31323765 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted Physical Activity (APA) group
Number of subjects: 44
Study 31323765 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 44
Study 28392264 — intervention group
Group type: COMPARATOR
Intervention: BodyPump (n=25)
Number of subjects: 92
Study 28392264 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual resistance training with a personal trainer (n=25)
Number of subjects: 92
Study 28392264 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-supervised individual resistance training (n=21)
Number of subjects: 92
Study 28392264 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising control group (n=21)
Number of subjects: 92
Study 26551184 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labor
Number of subjects: 162
Study 26551184 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 162
Study 22924758 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured balance and agility exercises in addition to normal physical training
Number of subjects: 779
Study 21187305 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated Fio(2) adjustment
Number of subjects: 32
Study 17531251 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepridil
Number of subjects: 29
Study 15011106 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized psychotherapeutic support during hospital stay
Number of subjects: 106
Study 15011106 — intervention group
Group type: COMPARATOR
Intervention: Classical music program
Number of subjects: 106
Study 11442551 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of aspirin every other day (n = 525)
Number of subjects: 1001
Study 11442551 — intervention group
Group type: COMPARATOR
Intervention: Aspirin placebo (n = 476)
Number of subjects: 1001
Study 10357955 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 10 mg at night
Number of subjects: 20
Study 10357955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7498099 — intervention group
Group type: EXPERIMENTAL
Intervention: Olestra (24 g) with moderate fibre (7 g/meal)
Number of subjects: 97
Study 7498099 — intervention group
Group type: EXPERIMENTAL
Intervention: Olestra (24 g) with high fibre (24 g/meal)
Number of subjects: 97
Study 7498099 — intervention group
Group type: COMPARATOR
Intervention: Placebo with moderate fibre (7 g/meal)
Number of subjects: 97
Study 7498099 — intervention group
Group type: COMPARATOR
Intervention: Placebo with high fibre (24 g/meal)
Number of subjects: 97
Study 7498099 — intervention group
Group type: EXPERIMENTAL
Intervention: Olestra (24 g)
Number of subjects: 97
Study 7498099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 1955634 — intervention group
Group type: EXPERIMENTAL
Intervention: Phazer
Number of subjects: 8
Study 1955634 — intervention group
Group type: EXPERIMENTAL
Intervention: Pricker
Number of subjects: 8
Study 1955634 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified prick tests
Number of subjects: 8
Study 1955634 — intervention group
Group type: EXPERIMENTAL
Intervention: Stallerkit
Number of subjects: 8
Study 1955634 — intervention group
Group type: EXPERIMENTAL
Intervention: Morrow Brown
Number of subjects: 8
Study 1955634 — intervention group
Group type: EXPERIMENTAL
Intervention: Allerkit
Number of subjects: 8
Study 1955634 — intervention group
Group type: EXPERIMENTAL
Intervention: Stallerpointe
Number of subjects: 8
Study 1955634 — intervention group
Group type: EXPERIMENTAL
Intervention: Wyeth Needle
Number of subjects: 8
Study 6958195 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis during mental stress recall
Number of subjects: 0
Study 6958195 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental stress (mental arithmetic)
Number of subjects: 0
Study 6958195 — intervention group
Group type: COMPARATOR
Intervention: Control (unstressed subjects)
Number of subjects: 0
Study 6958195 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental stress
Number of subjects: 0
Study 30951167 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg per-oral morphine
Number of subjects: 49
Study 30951167 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg per-oral naltrexone
Number of subjects: 49
Study 30951167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 29911741 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-induced weight loss only (D)
Number of subjects: 240
Study 29911741 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-induced weight loss plus exercise (D + E)
Number of subjects: 240
Study 27253693 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon-finance approved cookstove intervention
Number of subjects: 187
Study 27253693 — intervention group
Group type: COMPARATOR
Intervention: Traditional stoves (control)
Number of subjects: 187
Study 24296163 — intervention group
Group type: EXPERIMENTAL
Intervention: Flowable resin composite (Tetric Evo Flow)
Number of subjects: 34
Study 24296163 — intervention group
Group type: COMPARATOR
Intervention: Conventional resin-based sealant (Helioseal F)
Number of subjects: 34
Study 22855916 — intervention group
Group type: EXPERIMENTAL
Intervention: Porridge made with pinhead oats (P)
Number of subjects: 13
Study 22855916 — intervention group
Group type: COMPARATOR
Intervention: Porridge made with rolled oats (R)
Number of subjects: 13
Study 20696421 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment program
Number of subjects: 45
Study 20696421 — intervention group
Group type: COMPARATOR
Intervention: Waitlist-control condition
Number of subjects: 45
Study 20696421 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment program (after waitlist)
Number of subjects: 45
Study 18281409 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (0.8-1.8 mg/kg per day)
Number of subjects: 222
Study 18281409 — intervention group
Group type: EXPERIMENTAL
Intervention: Osmotically released methylphenidate (18-54 mg/day)
Number of subjects: 222
Study 18281409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study 18281409 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine after methylphenidate
Number of subjects: 222
Study 18281409 — intervention group
Group type: EXPERIMENTAL
Intervention: Osmotically released methylphenidate after atomoxetine
Number of subjects: 222
Study 15689584 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral pallidal stimulation
Number of subjects: 22
Study 15689584 — intervention group
Group type: COMPARATOR
Intervention: Neurostimulation
Number of subjects: 22
Study 12603516 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural sleep intervention (4-week duration)
Number of subjects: 155
Study 10229280 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive ankle taping
Number of subjects: 12
Study 10229280 — intervention group
Group type: COMPARATOR
Intervention: No tape (control)
Number of subjects: 12
Study 8634927 — intervention group
Group type: EXPERIMENTAL
Intervention: Interlocking nails
Number of subjects: 107
Study 8634927 — intervention group
Group type: COMPARATOR
Intervention: Ender nails
Number of subjects: 107
Study 1473428 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose Al antacid (1 tablet four times a day)
Number of subjects: 11
Study 1473428 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (800 mg at bedtime)
Number of subjects: 11
Study 1473428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 6426646 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 valent pneumococcal vaccine
Number of subjects: 242
Study 6426646 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin
Number of subjects: 242
Study 6426646 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 242
Study 30615000 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic septoplasty (n: 25)
Number of subjects: 39
Study 30615000 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal septoplasty (n: 14)
Number of subjects: 39
Study 29139301 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (10 or 25 mg/day)
Number of subjects: 0
Study 29139301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27511856 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F‐Fluciclovine PET-CT
Number of subjects: 41
Study 22289010 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard course with role play
Number of subjects: 48
Study 22289010 — intervention group
Group type: COMPARATOR
Intervention: Alternative course with no role play
Number of subjects: 48
Study 20453546 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid/carboxymethylcellulose (HA/CMC) dressing
Number of subjects: 53
Study 20453546 — intervention group
Group type: COMPARATOR
Intervention: Control (unpacked side)
Number of subjects: 53
Study 18395910 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic hemoclip placement (EHP)
Number of subjects: 41
Study 18395910 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic band ligation (EBL)
Number of subjects: 41
Study 16521845 — intervention group
Group type: COMPARATOR
Intervention: CHO (9.3% carbohydrate solution)
Number of subjects: 16
Study 16521845 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO-PRO (9.3% carbohydrate solution plus 1.5% protein)
Number of subjects: 16
Study 12180579 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 200 mg
Number of subjects: 60
Study 12180579 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 300 mg
Number of subjects: 60
Study 12180579 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 60
Study 10494641 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary oxygen (2 L/min)
Number of subjects: 40
Study 10494641 — intervention group
Group type: COMPARATOR
Intervention: Room air
Number of subjects: 40
Study 8740798 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel at dose levels of 135, 170, 200, 250, and 300 mg/m2 (24-hour infusion); 250 mg/m2 (one-hour infusion)
Number of subjects: 31
Study 8740798 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide at a dose of 1.6 g/m2 i.v. bolus daily for 3 days with mesna uroprotection
Number of subjects: 31
Study 8391065 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy (seven further cycles of CDE: cyclophosphamide 1 g/m2, doxorubicin 45 mg/m2, etoposide 100 mg/m2)
Number of subjects: 687
Study 8391065 — intervention group
Group type: COMPARATOR
Intervention: Follow-up (no further chemotherapy)
Number of subjects: 687
Study 8391065 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy (seven further cycles of CDE)
Number of subjects: 687
Study 8391065 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms (maintenance and follow-up)
Number of subjects: 687